A. Peillon

Long-Term, Open-Label Extension Study of the Efficacy and Safety of Epicutaneous Immunotherapy for Peanut Allergy in Children: PEOPLE 3-Year Results.

William H. Yang, H. Sampson, V. Mahler, 2020, The Journal of allergy and clinical immunology.

Transmission probabilities of HIV and herpes simplex virus type 2, effect of male circumcision and interaction: a longitudinal study in a township of South Africa

E. Gassiat, A. Puren, A. Latouche, 2009, AIDS.

Sustained Unresponsiveness to Peanut After Long-Term Peanut Epicutaneous Immunotherapy.

H. Sampson, F. de Blay, D. Campbell, 2020, The journal of allergy and clinical immunology. In practice.

Factors limiting the use of technical assistance and prospects for use in ALS patients

M. Bocca, S. Besnard, A. Peillon, 2018, Modelling Measurement and Control C.

An evaluation of factors influencing response to epicutaneous immunotherapy for peanut allergy in the PEPITES trial.

H. Sampson, D. Fleischer, D. Campbell, 2020, Allergy and asthma proceedings.

Epicutaneous immunotherapy for peanut allergy modifies IgG4 responses to major peanut allergens.

H. Sampson, S. Koppelman, W. Agbotounou, 2019, The Journal of allergy and clinical immunology.

Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy.

A. Burks, H. Sampson, B. Vickery, 2023, The New England journal of medicine.